Fetch.ai and LiquidChefs Partner to Enable Sustainable AI-Powered Supply Chain Services

This partnership paves the way for increased transparency within supply chains using autonomous economic agents and will be showcased at WEF Davos 2022

Fetch.ai x LiquidChefs

Fetch.ai x LiquidChefs

CAMBRIDGE, England, Dec. 14, 2021 (GLOBE NEWSWIRE) — Fetch.ai (https://fetch.ai/), a Cambridge-based artificial intelligence lab building an open-access decentralized machine learning network for smart infrastructure, has announced a partnership with LiquidChefs, an on-location food beverage services company.

One of the main challenges facing modern supply chains is access to data, which is crucial for effective decision-making. This data is not always available as supply chains lack transparency due to their sheer size and other complexities. As a result, many organisations are faced with an assortment of manual and digital systems that effectively trap information within functional silos, hampering the decision-making process by providing an incomplete picture.

The partnership between Fetch.ai and LiquidChefs aims to utilize Fetch.ai’s Autonomous Economic Agents integrated with its Search and Discovery Framework to build local and transparent supply chains, allowing LiquidChefs to search and connect with any sustainable supplier in its immediate vicinity. At launch, it will support a select number of suppliers including Bäckerei-Konditorei-Café Weber, BierVision Monstein AG, Black Peak Brauerei, Adank Davos AG, and Liberty Coffee Roasters.

By digitalising and automating the LiquidChefs supply chain, Fetch.ai infrastructure will create a decentralised supply chain marketplace. This marketplace connects buyers and suppliers digital agents, in real time, to support dynamic, scalable, multi-agent supply chains. This will allow individuals, organisations and assets to be represented as digital agents which work autonomously based on the users’ needs and preferences, such as finding local and sustainable suppliers. The decentralized supply chain marketplace will be showcased at the Davos World Economic Forum in 2022.

“The pandemic has exposed the challenges and risks of supply chains in particular, the over-reliance on centralized locations as a source of critical products,” said Humayun Sheikh, CEO of Fetch.ai. “Through this partnership with LiquidChefs, Fetch.ai will create a more reliable, transparent and efficient supply chain which will trace the sustainability of products and services.”

“The nature of hospitality is collaborative and this understanding is integral to create sustainable spaces in our industry. We are excited to partner with Fetch.ai and incorporate cutting edge technologies like Blockchain, Multi-agent systems, and AI to create verified and transparent supply chains for our services,” said Adam Solomon, Director of LiquidChefs.

About Fetch.ai

Fetch.ai is building the infrastructure required for autonomous software agents to begin performing useful economic work on behalf of individuals, machines, businesses, and organizations. Fetch.ai’s network is based around open-source technology and gives users access to the power of AI on a world-scale secure dataset to carry out complex coordination tasks in the modern economy. For more information, please visit https://www.fetch.ai.

Press contact: info@fetch.ai

About LiquidChefs

LiquidChefs is a premium mobile bar company specializing in the supply of all things liquid. From the supply of coffee, smoothie, cocktail and juice bars to slick and stylish bartenders that bring unforgettable energy to events, LiquidChefs has been servicing the hospitality sector for the past 13 years. Over the past few years, the ‘all things liquid’ became soup, and then food catering services too. Since 2009, LiquidChefs has been a part of some of the most unforgettable events at the World Economic Forum.

LiquidChefs focuses on making decisions relating to supplier partnerships based on factors like location, framing practises, inclusion and diversity, gender related pay, worker living wage rates, forced labour, access to unions, working conditions and access to jobs among many other governance issues too.

For more information, please visit https://www.liquidchefs.co.uk/

Related Images

Image 1: Fetch.ai x LiquidChefs

This content was issued through the press release distribution service at Newswire.com.

Attachment

Intuitive reaches 10 million procedures performed using da Vinci Surgical Systems

Milestone serves as foundation for continued innovative improvement in minimally invasive surgery

SUNNYVALE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) — Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the number of robotic-assisted surgical procedures performed worldwide by surgeons using da Vinci surgical systems has surpassed 10 million.

“Surgeon use of da Vinci surgical systems in more than 10 million procedures reflects the benefits that high-quality, minimally invasive surgery conveys to patients, families, and the healthcare systems that care for them,” said Intuitive CEO Gary Guthart. “While we are proud of this milestone and momentum, this is really a moment to look at what we’ve learned from these 10 million procedures and ask ourselves how we can apply that to improving the field of surgery for years to come.”

Cleared for use by the U.S. Food & Drug Administration in 2000, there are more than 6,500 da Vinci surgical systems installed in 67 countries, and more than 55,000 surgeons worldwide have trained on the use of da Vinci systems.

“We have always sought to deliver solutions that meet our customers’ needs—better patient outcomes, better patient experiences, better care team experiences, and a lower total cost to treat per patient episode,” said Guthart. “We will continue to drive outcomes-focused innovation for our customers to help their patients for the next 10 million procedures and beyond.”

Intuitive plans to continue taking its deep and broad experience from these procedures and putting it to work for customers in the form of personalized surgical training programs, continued innovation in systems, instruments and accessories, and an expanded ecosystem of customer services, evidence development, and digital support and solutions.

There are nearly 70 representative clinical uses for da Vinci systems, spanning clinical specialties, including urology, gynecology, thoracic surgery, general surgery, and transoral surgery.

“The growing base of clinical evidence—nearly 30,000 studies on robotic-assisted surgery—and the increasing ability of surgeons, hospitals, and healthcare systems to assess their own data and patient outcomes, have been major drivers of surgeon adoption and the procedure growth that follows,” said Guthart. “Our customers are dedicated to the health and well-being of their patients—they don’t adopt and continue using technology that does not meet their needs.”

Intuitive’s latest, fourth generation of robotic systems, the da Vinci X, Xi, and its single-port system (SP), have continued to evolve through technology, as well as the addition of instruments, features, and digital support.

The company’s innovation in robotic-assisted technology includes development of its Ion endoluminal system designed to enable robotic-assisted lung biopsy.

About Intuitive

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. As part of our mission, we believe that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints.

Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to its offerings and develops, manufactures, and markets the da Vinci Surgical System and the Ion endoluminal system.

Product and brand names/logos are trademarks or registered trademarks of Intuitive Surgical or their respective owner. See www.intuitive.com/trademarks.

For more information, please visit the Company’s website at www.intuitive.com.

About the da Vinci Surgical System

There are several models of the da Vinci Surgical System. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery. Da Vinci systems offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.

For more information, please visit the company’s website at www.intuitive.com.

About Ion

Ion is Intuitive’s robotic-assisted platform for minimally invasive biopsy in the lung. The system features an ultra-thin, ultra-maneuverable catheter that allows navigation far into the peripheral lung and provides the unprecedented stability necessary for precision in biopsy. Visit www.intuitive.com/en-us/products-and-services/ion

Important Safety Information

For Important Safety Information, indications for use, risks, full cautions and warnings, please refer to www.intuitive.com/safety.

Forward-Looking Statements

This press release contains forward-looking statements about Intuitive and our plans to continue to improve our products to advance minimally invasive surgery, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, our ability to build upon the robust clinical and technological foundation created, our ability to work to broaden our capacity, our ability to invest for future innovation and growth, competitive developments and customer’s willingness to continue using our products. We undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

Contact
US/GLOBAL: Global Public Affairs
Intuitive Surgical
corp.comm@intusurg.com
+1-202-997-7373
+1-470-331-0327

WillScot Mobile Mini Acquires Regional Modular And Storage Services Provider In Midwest United States

PHOENIX, Dec. 14, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced that it closed the acquisition of McDonald Modular Solutions. The transaction was funded with cash on hand and borrowings under the Company’s revolving credit agreement. This acquisition adds approximately 1,300 modular units and over 300 storage units in the Company’s existing markets in Michigan and Ohio.

Brad Soultz, Chief Executive Officer, commented, “I am excited to welcome the employees of McDonald Modular Solutions to our team at WillScot Mobile Mini. This transaction expands our presence and capabilities in the greater Midwest region. Consistent with our M&A strategy, we look forward to providing our ‘Ready to Work’ value proposition to new customers and applying our commercial and organizational best practices, while leveraging our scalable technology platform. Thank you to both our new and existing team members who are now working together to integrate our operations.”

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating value creation, the Company’s share price, and the Company’s future performance. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These risks include, without limitation, the risks and uncertainties described in the periodic reports we file with the SEC from time to time (including our Form 10-K/A for the year ended December 31, 2020), which are available through the SEC’s EDGAR system at www.sec.gov and on our website. Any forward-looking statement speaks only at the date which it is made, and WillScot Mobile Mini disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Mobile Mini Holdings Corp.

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of over 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Contact Information

Investor Inquiries:

Nick Girardi

nick.girardi@willscotmobilemini.com

Media Inquiries:

Scott Junk

scott.junk@willscotmobilemini.com

Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant

Previously Reported In Vitro Data Demonstrating that Individual Omicron Mutations Were Not Associated with ADG20 Escape Do Not Translate to Omicron Authentic and Pseudovirus Assays

WALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided an update following external in vitro analyses to evaluate neutralizing activity of ADG20 against the Omicron SARS-CoV-2 variant. The in vitro data generated through both authentic and pseudovirus testing of the Omicron variant show a greater than 300-fold reduction in neutralizing activity of ADG20 against Omicron. Additional analyses are ongoing, and the company plans to engage with regulatory and government agencies to assess the role ADG20 can play for the prevention and treatment of COVID-19, particularly as the industry’s understanding of the epidemiology and impact of Omicron and potential new variants develops.

“Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we anticipated that ADG20 would retain neutralizing activity against Omicron, consistent with activity observed in in vitro models with all other known variants of concern,” said Tillman Gerngross, Ph.D., chief executive officer of Adagio. “While the individual mutations present in the Omicron receptor binding domain were not associated with escape from ADG20 in the context of an original strain of the virus, new data show that the combination of mutations present in the Omicron spike protein led to a reduction in ADG20 neutralization that was not suggested by prior data. The continued prevalence of the Delta variant in the U.S. and other countries, evolution of SARS-CoV-2 variants and potential future coronaviruses means a multitude of therapies and approaches are needed. With an expert team committed to advancing antibody solutions that combat this unprecedented pandemic and a strong balance sheet, we’re conducting additional analyses to assess the optimal path forward with ADG20 as both a prophylactic and treatment option for COVID-19.”

ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year with a single injection. In previously disclosed in vitro studies, ADG20 retained activity against prior variants of concern including Alpha, Beta, Delta and Gamma. In addition, in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the Lambda, Mu and Delta plus variants. The safety and efficacy of ADG20 have not been established, and ADG20 is not authorized or approved for use in any country.

Adagio is currently evaluating ADG20 in global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Based on the in vitro findings related to Omicron, Adagio plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa, where Omicron has emerged as the dominant variant. Adagio is evaluating next steps for its ADG20 program.

In vitro analyses were also conducted on ADG10, a second mAb in development, which showed minimal neutralizing activity against the Omicron variant in both authentic and pseudovirus neutralization assays.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of future program updates and the initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the additional and ongoing analyses to evaluate the activity of ADG20 against the Omicron variant and the potential of ADG20 to play a role as both a prophylactic and a treatment option for COVID-19; the risk/benefit profile of our product candidates to patients; and the adequacy of our cash, cash equivalents and marketable securities. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and in Adagio’s future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact: Investor Contact:
Dan Budwick, 1AB Monique Allaire, THRUST Strategic Communications
Dan@1abmedia.com monique@thrustsc.com

JLL Aligns with HqO, an Industry Leader in Workplace Experience Technology

Tenant engagement strategies are key for return to office plans

CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) — Retaining, attracting, and building stronger relationships with tenants returning to the office will be critical for the long-term success of commercial office buildings. To further enhance tenant engagement and experience across its portfolio of managed buildings, JLL has aligned with HqO, an industry-leading workplace experience platform, to bring world-class workplace experiences to JLL clients both on-site and digitally.

JLL has made a strategic investment in HqO as the preferred service provider for workplace experience because of its commitment to delivering best-in-class technology and customer success. HqO’s product consists of an award-winning app, analytics suite, hybrid work tools, and a flex space management system.

The platform allows JLL’s Experience Management group, which combines best-in-class programming and service both digitally and physically, to streamline the workplace experiences delivered to tenants through an easy-to-use app and provide valuable data and feedback for landlords to make more informed decisions that drive greater tenant engagement.

“JLL has committed to being an industry leader in technology, which includes creating strategic alignments with firms like HqO,” said Jay Koster, President of Investor Services, JLL. “Through this strategic alignment, we have been able to work in lockstep with HqO to help customize the user experience to fit the evolving needs of the industry during this crucial inflection point.”

“In today’s market, experience and amenities have gone from niceties to necessities,” added Tom Larance, Head of Experience Management at JLL. “HqO will help us solve how technology can best serve our clients and office communities, today and in the future.”

HqO, a JLL Spark investment in 2018, has now secured a follow-on corporate investment from JLL, becoming one of the latest additions to JLL’s proptech ecosystem.

“JLL Spark has been a prominent investor in HqO since 2018 and we are excited to expand our relationship to solve the needs of JLL’s clients globally,” said Yishai Lerner, Co-CEO at JLL Technologies. “HqO is a must-have product for any landlord seeking to retain, attract and build stronger tenant relationships. Together, we will further drive technology innovation within the real estate sector.”

“JLL has been a leader in the industry by operating at the intersection of technology, property management, and experience strategy,” said Chase Garbarino, CEO and Co-Founder of HqO. “This aligns perfectly with how we at HqO serve our customers. As the preferred service provider for workplace experience, we are excited to deepen our relationship with JLL and deliver our joint clients a complete end-to-end workplace experience that truly revolutionizes the way people value the office.”

JLL’s 2,300 property management experts in the U.S. provide comprehensive real estate services in more than 1,200 buildings totaling more than 208 million square feet.

For more news, videos and research resources on JLL, please visit our newsroom.

About HqO

As the leader in workplace experience technology, HqO is revolutionizing how people connect with each other and the places they work — right from the palm of their hands. Composed of an award-winning app, analytics suite, hybrid work tools, and a flex space management system, the HqO Workplace Experience Platform empowers property teams and companies to create personalized experiences that engage and delight the people at their properties and inform data-driven decision making.

Active in over 200 million square feet of commercial real estate and across 24 countries, HqO helps build meaningful relationships with the people in the workplace every day. For more information, visit www.hqo.com.

About JLL

JLL (NYSE: JLL) is a leading professional services firm that specializes in real estate and investment management. JLL shapes the future of real estate for a better world by using the most advanced technology to create rewarding opportunities, amazing spaces and sustainable real estate solutions for our clients, our people and our communities. JLL is a Fortune 500 company with annual revenue of $16.6 billion, operations in over 80 countries and a global workforce of more than 95,000 as of September 30, 2021. For further information, visit jll.com.

Connect with us:

https://www.linkedin.com/company/jll
https://twitter.com/jll?s=21
https://instagram.com/jll?utm_medium=copy_link
https://www.facebook.com/JLLUSA/

Contact: Kristen Murphy, JLL Senior Manager, Public Relations
Phone: +1 617 848 1572
Email: Kristen.Murphy@am.jll.com

Feedzai Grows 125%, Hires new CRO, General Counsel, and brings in a new independent board member

  • 125% year-over-year ARR growth in Q3 with multiple new customers in North America, Europe, Latin America, and Asia.
  • New Chief Revenue Officer and General Counsel join the company.
  • Christian Smith, CRO at Splunk joins Feedzai as new independent board member.

LISBON, Portugal and SAN MATEO, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) — Feedzai, the leading RiskOps platform, today announced that has experienced a 125% year-over-year growth in new Annual Recurring Revenue (ARR) in Q3. Large multi-year enterprise deals closed in the US, EMEA, APAC, and LATAM with 100% year-to-date growth in new logos.

Feedzai recently announced the evolution of financial risk management, with the introduction of the world’s first RiskOps Platform in a single, comprehensive cloud-based platform to manage multiple forms of risk and compliance. Today, more than 20 percent of the world’s money flows through Feedzai while the company secures the bank accounts of 1 in every five people. In August 2021, Feedzai acquired Revelock and became the world’s largest Financial Intelligence Network (FIN), a vault of more than a trillion data points, sessions, and profiles of both good and bad actors.

“Feedzai keeps growing at a steady rate and we are winning the most important deals in this space. The partnerships we’re forging mean that we will be redefining the way companies operationalize risk in the years to come, with a long-lasting positive impact for hundreds of millions of people every day,” said Nuno Sebastiao, Co-founder, and CEO of Feedzai. “It was also time to step back and reevaluate not just the tools we use to fight fraud or money laundering, but the overall approach we take to developing risk management solutions. RiskOps is a unified theory that allows teams to move from reactionary, one-off point solutions to a comprehensive platform that removes the silos and adds real substance and meaning to their work.

As part of the growth, Feedzai has achieved several important milestones, including:

Business Performance and Geographic Expansion – Feedzai reports a 125% year-over-year growth in new Annual Recurring Revenue (ARR) in Q3 and a 100% year-to-date growth in new logos. Additionally, the company has expanded its global footprint with new multi-year deals in Malaysia, Germany, Spain, the US, and many other markets. Feedzai is now also protecting one of the biggest money transfer brands in the world, a major domestic debit and credit card brand in Brazil, one of the world’s largest Islamic banks, a leading P2P provider in Spain and Europe, among many others.

Leadership Strengthening – The company keeps attracting top talent to its C-suite and a new independent board member.

  • Christian Smith, Independent Board Member – joins Feedzai’s board of directors. With over 25 years of experience, Christian is currently the CRO of Splunk and has focused on executive sales and marketing leadership specializing in Cloud and Hybrid Go To Markets in companies such as Nintex and Oracle.
  • Elliott Limb, Chief Revenue Officer – a seasoned banking executive twice named as one of the Top 50 Most Influential Leaders in fintech globally. Former Chief Customer Officer at Mambu with leadership roles at Citibank, Finastra, and Barclays.
  • Patricia Marques Ferreira, General Counsel – with over 20 years of experience, Patricia was the Head of Legal at Outsystems and worked at PLMJ, one of the most innovative international law firms according to the Financial Times.
  • Pedro Barata, Chief Product Officer – After two years as SVP of Product and prior to that having assembled and led the Customer Success department, Pedro was appointed Chief Product Officer, where he leads product development and management to bring the most advanced financial crime-fighting technology to market.

Market category leader through innovation – Feedzai’s RiskOps platform has a fully extensible architecture that allows to instantly go from sandbox to production, human-centered AI with individualized risk assessment embedded across the entire system, and a collaborative analytics suite to further break down the silos between fraud, AML, compliance, and risk teams by putting all the data, tools and analytics in one single space.

Investment in research has been steadily increasing, with 100% patent submission growth in the last two years, more than 10 top tier scientific peer-reviewed papers since the beginning of the year, and multiple awards, such as 2021 Fast Company World Changing Idea (AI and Data category finalist) and 2021 Fintech Breakthrough Award.

Examples of innovations developed by Feedzai Research include a large-scale point-of-compromise detection algorithm, industry-leading AutoML algorithms, automatic detection of model degradations, automatic tuning of rules, human-understandable machine learning explanations, model fairness mitigation algorithms, alert suppression techniques, biometric identification of trojan attacks and more.

According to the latest Quarterly Financial Crime Report, which analysed consumer spending trends from more than 1.5 billion global transactions, consumers’ shift to digital banking has gotten stronger. The data reveals a continuous move to cashless transactions, with a 146% increase in P2P payments, a 44% decrease in cash transactions, and a 109% increase in online transactions, to nearly double the number of card-present or in-person transactions. With this focus on digital payments, financial criminals have also shifted their targets online.

Pictures can be downloaded here.

About Feedzai
Feedzai is the world’s first RiskOps platform, and the market leader in safeguarding global commerce with today’s most advanced cloud-based risk management platform, powered by machine learning and artificial intelligence. Feedzai is securing the transition to a cashless world while enabling digital trust in every transaction and payment type. The world’s largest banks, processors, and retailers trust Feedzai to protect trillions of dollars and manage risk while improving the customer experience for everyday users, without compromising privacy. Feedzai is a Series D company and has raised $282M to date with a current valuation of $1.5B. Its technology protects 800 million people in 190 countries. For more information, visit feedzai.com.

Press Contacts
Igor Carvalho
Head of Global Communications, Feedzai
igor.carvalho@feedzai.com

Philips provides update on composition of its Supervisory Board

December 14, 2021

  • Herna Verhagen and Sanjay Poonen proposed as new members of Philips’ Supervisory Board
  • Paul Stoffels and Marc Harrison proposed for reappointment as members of the Supervisory Board
  • Neelam Dhawan to retire from the Supervisory Board after third consecutive term

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that its Supervisory Board will propose the appointments of Mrs. Herna Verhagen and Mr. Sanjay Poonen as new members of the Supervisory Board at the Annual General Meeting of Shareholders (AGM), which will be held on May 10, 2022. Furthermore, Dr. Paul Stoffels and Dr. Marc Harrison, whose first terms expire in 2022, will be proposed for re-appointment as members of the Supervisory Board. Mrs. Neelam Dhawan, who joined Philips’ Supervisory Board in 2012, will retire from the Board after her third consecutive term, effective upon closing of the 2022 AGM.

“We are very pleased to nominate Mrs. Herna Verhagen and Mr. Sanjay Poonen as new members of Philips’ Supervisory Board, supporting the company to deliver on its purpose of improving people’s health and well-being through innovation,” said Feike Sijbesma, Chairman of the Supervisory Board of Royal Philips. “With her proven track record in driving a customer-first company culture and a background in e-commerce logistics, Mrs. Verhagen will bring valued and new perspectives to the Supervisory Board, while Mr. Poonen’s extensive experience in enterprise IT will further strengthen the Supervisory Board’s digital competencies.”

“We are also very pleased that Dr. Paul Stoffels, the current Vice Chair, and Dr. Marc Harrison remain available as members of the Board,” added Mr. Sijbesma. “Their expertise and experience in healthcare innovation is extremely valuable as Philips aims to support the transformation of healthcare with new health technology solutions along the health continuum.”

“On behalf of the Executive Committee and the Supervisory Board, I would like to express my deep gratitude to Neelam Dhawan for her long-term counsel and support since 2012,” said Frans van Houten, CEO of Royal Philips. “Her in-depth knowledge of the IT industry, including research, software engineering, and services has been indispensable during Philips’ transformation into a health technology leader. We look forward to continue to grow Philips, supported by a diverse and experienced Supervisory Board, aiming to support consumers to lead a healthy life and our healthcare customers achieve the Quadruple Aim of better health outcomes, improved patient and staff experiences, and lower cost of care.”

Mrs. Verhagen (Dutch, 1966) has been CEO and Chair of the Board of Management of PostNL since 2012. Under her leadership, PostNL executed a strategic transformation from a mail delivery company into a growing postal and e-commerce logistic solutions provider. Prior to her role as CEO, Mrs. Verhagen served as a member of the Management Board of PostNL, and was Managing Director Parcels and International PostNL.

Mr. Poonen (American, 1969) has held various executive leadership positions in the software industry, including most recently as Chief Operating Officer for cloud computing company VMware. In this role he was responsible for all business functions, including sales, services, support, marketing and alliances including strategic agreements with Amazon, Microsoft and Google. Prior to VMware, he was President at SAP, where he led analytics, data management and vertical industry solutions.

Subject to AGM approval, Mrs. Verhagen and Mr. Poonen will join a diverse and experienced Supervisory Board, consisting of members from Europe, North America and Asia with wide-ranging business experiences, including in the medical technology, healthcare, pharmaceuticals, IT, engineering and consumer goods industries. For more information about Philips’ Supervisory Board, please follow this link.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Attachments

Meiogenix Announces $13 Million Series A Financing Round Led by Sofinnova Partners

Co-investors include Genoa Ventures, Bpifrance, Casdin Capital and Alexandria Venture Investments

Paris, France, Dec. 14, 2021 (GLOBE NEWSWIRE) — Meiogenix, an agriculture biotech company using the process of Chromosome Editing to expand genetic diversity in food and agriculture, announced today the closing of a $13 million (€11 million) Series A financing round, led by Sofinnova Partners, with participation from Genoa Ventures, Bpifrance, Casdin Capital and Alexandria Venture Investments.

“We’re at an exciting stage of our development,” said Luc Mathis, CEO of Meiogenix. “The Series A funding will provide capital for our implementation in the United States and further product development. The caliber of our global investor syndicate reflects our international expansion strategy to pursue innovation in Europe and focus product development in North America.”

Meiogenix has developed an innovative approach to common problems in agriculture, addressing key global food and industrial challenges. Meiogenix is applying gene and chromosome editing technologies to accelerate nature’s generation of biodiversity through the mixing of parental genomes during plant reproduction. This helps expedite the lengthy process of plant varieties selection and also leads to increased biodiversity, lost during the systematic selection of crops for high yield and long shelf life. The ability to restore a plant’s immunity to pests and diseases, and improve quality, taste and flavor in many crops also has the potential to revolutionize the AgriFood Tech sector. Key benefits of the platform include more access to natural food products for customers and less chemicals required in growing food.

“This investment reflects our expanding interest in the application of biotech in agriculture,” said Michael Krel, Partner at Sofinnova Partners, and a key member of the Sofinnova Industrial Biotech Funds. “Meiogenix has the potential to revolutionize the way we enhance the natural properties of plants so that they are more resistant to viruses, better tasting, and produce higher yield. We are confident in this team’s ability to bring its groundbreaking science to significantly improve the safety and sustainability of our global food systems.”

The Meiogenix platform addresses the $50 billion commercial seed market and breeding capabilities of large and essential crops like corn, wheat, rice, soybeans and tomatoes.

“Our investment in Meiogenix is based on their unique approach to solving critical bottlenecks in food production for the commercial seed industry, a rapidly growing market expected to surpass $60 billion by 2025,” said Jenny Rooke, Ph.D., Founder and Managing Director of Genoa Ventures. “The agriculture industry is ripe for translating great innovations in life sciences to agricultural applications, and leaders in the space are investing heavily in the latest gene editing technologies to accelerate improved product development. Meiogenix’s relationships with innovative industry leaders like Bayer further demonstrate the enormous potential for the Meiogenix platform to usher in the next stage of progress for the agricultural industry.”

About Meiogenix
Meiogenix is a pioneer in chromosome editing, developing broadly applicable gene and chromosome editing capabilities that restore essential biodiversity to agriculture, enabling unity between natural ecosystems and our food production. Meiogenix has collaborations with Cornell and Bayer to help develop crops that improve our food supply while caring for our environment. For more information, see www.meiogenix.com or contact us at: info@meiogenix.com

This content was issued through the press release distribution service at Newswire.com.